Trial reportBMC veterinary research2016
Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.
Trial report in BMC veterinary research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- Immunomodulatory and immunosuppressive drug protocols in the treatment of canine primary immune thrombocytopenia, a scoping review.Acta veterinaria Scandinavica · 2021Article
- "Acute onset tetraplegia associated with immune-mediated thrombocytopenia and suspected secondary intraspinal hemorrhage in a dog".Clinical case reports · 2019Article
- Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim.BMC veterinary research · 2016Article
- Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes.Journal of veterinary internal medicineArticle
- Plasma concentration of thrombopoietin in dogs with immune thrombocytopenia.Journal of veterinary internal medicineArticle
- Use of Immunosuppression, Romiplostim, and Splenectomy to Achieve Remission in a British Shorthair Cat With Primary Immune-Mediated Thrombocytopenia.Journal of veterinary internal medicineArticle
- ACVIM consensus statement on the diagnosis of immune thrombocytopenia in dogs and cats.Journal of veterinary internal medicineArticle
- ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats.Journal of veterinary internal medicineArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune thrombocytopenia (ITP) in dogs is analogous to that in humans. Romiplostim, a novel thrombopoietin receptor (TPO-R) agonist, is currently used for the treatment of refractory ITP in humans, but not in dogs. Here, we describe the response to romiplostim in five dogs with refractory ITP. Five dogs with severe and refractory ITP (three primary and two secondary) received romiplostim subcutaneously. Four dogs were administered 3-5 μg/kg and one dog received 10-13 μg/kg body weight once weekly.
resultsRomiplostim was well-tolerated and administration was associated with an increase in platelet counts in all five dogs. Four of the five dogs entered remission and relapses were not observed over a follow-up period of 3-10 months.
conclusionsRomiplostim is effective in the treatment of ITP in dogs at least as well as in humans. This finding may help to develop and use new therapeutics for ITP in dogs and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.